{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:43:31Z","timestamp":1761965011852},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.humpath.2018.07.002","type":"journal-article","created":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T10:23:03Z","timestamp":1531909383000},"page":"121-130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis"],"prefix":"10.1016","volume":"81","author":[{"given":"Kazuma","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koko","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Seyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.07.002_bb0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/107327480601300405","article-title":"Lymphangioleiomyomatosis","volume":"13","author":"Taveira-DaSilva","year":"2006","journal-title":"Cancer Control"},{"key":"10.1016\/j.humpath.2018.07.002_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1378\/chest.07-0898","article-title":"Lymphangioleiomyomatosis: a clinical update","volume":"133","author":"McCormack","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.humpath.2018.07.002_bb0015","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.pas.0000172192.25295.45","article-title":"Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis","volume":"29","author":"Kumasaka","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0020","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.07.002_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphaingoleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2018.07.002_bb0030","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","article-title":"Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis","volume":"11","author":"Takeda","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.humpath.2018.07.002_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signaling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signaling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1440-1827.2001.01255.x","article-title":"Chromogenic in situ hybridization of HER2\/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy","volume":"51","author":"Kumamoto","year":"2001","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2018.07.002_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2008.10.009","article-title":"Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas","volume":"65","author":"Lopez-Malpartida","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2018.07.002_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2018.07.002_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/thx.2006.071811","article-title":"Lymphangioleiomyomatosis\u2014presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets","volume":"62","author":"Watz","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.humpath.2018.07.002_bb0065","first-page":"3353","article-title":"Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis","volume":"35","author":"Gezegorek","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.humpath.2018.07.002_bb0070","doi-asserted-by":"crossref","first-page":"E3855","DOI":"10.1073\/pnas.1510733112","article-title":"EGFR inhibition evokes innate drug resistance in lung cancer cell by preventing Akt activity and thus inactivating Ets-1 function","volume":"112","author":"Phuchareon","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2018.07.002_bb0075","doi-asserted-by":"crossref","first-page":"27923","DOI":"10.18632\/oncotarget.4736","article-title":"Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer","volume":"6","author":"Cuenca-L\u00f3pez","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.07.002_bb0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jop.12024","article-title":"Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas","volume":"42","author":"Oikawa","year":"2013","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.humpath.2018.07.002_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2012.01.011","article-title":"Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations","volume":"318","author":"Han","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2018.07.002_bb0090","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/PAI.0000000000000014","article-title":"Cytoplasmic EGFR staining and gene amplification in glottic cancer: a better indicator of EGFR-driven signaling?","volume":"22","author":"Braut","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1097-0215(19960117)65:2<161::AID-IJC6>3.0.CO;2-X","article-title":"Cytoplasmic localization of EGF receptor in papillary thyroid carcinomas: association with the 150-kDa receptor form","volume":"65","author":"Ness","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2018.07.002_bb0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/jcp.2005.028373","article-title":"Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas","volume":"59","author":"Kersting","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0105","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/cas.13017","article-title":"Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer","volume":"107","author":"Mukai","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2018.07.002_bb0110","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/onc.2015.142","article-title":"Anti-HER3 monoclonal antibody patritumab sensitizes refractory non\u2013small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib","volume":"35","author":"Yonesaka","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2018.07.002_bb0115","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/1078-0432.CCR-08-1064","article-title":"High expression of HER3 is associated with a decreased survival in gastric cancer","volume":"14","author":"Hayashi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.07.002_bb0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bjc.6603613","article-title":"PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas","volume":"96","author":"Aubele","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2018.07.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1843","article-title":"Cytogenetic analysis of HER1\/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients","volume":"10","author":"Sassen","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.humpath.2018.07.002_bb0135","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2012.44.1956","article-title":"Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2\u2013positive breast cancer: result from a herceptin adjuvant trial","volume":"31","author":"Partridge","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.07.002_bb0140","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.3892\/ol.2017.6000","article-title":"Age-associated prognostic and predictive biomarkers in patients with breast cancer","volume":"13","author":"Kole\u010dkov\u00e1","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.humpath.2018.07.002_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2012.09.006","article-title":"Impact of age on epidermal growth factor receptor mutation in lung cancer","volume":"78","author":"Ueno","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humpath.2018.07.002_bb0150","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1086\/301804","article-title":"Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis","volume":"62","author":"Smolarek","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.humpath.2018.07.002_bb0155","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2018.07.002_bb0160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","article-title":"Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases","volume":"138","author":"Young","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.humpath.2018.07.002_bb0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00408-008-9087-5","article-title":"Lymphangioleiomyomatosis and tuberous sclerosis complex","volume":"186","author":"Chorianopoulos","year":"2008","journal-title":"Lung"},{"key":"10.1016\/j.humpath.2018.07.002_bb0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/21678707.2016.1148597","article-title":"Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis","volume":"4","author":"Taveira-DaSilva","year":"2016","journal-title":"Expert Opin Orphan Drugs"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718302594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T16:25:21Z","timestamp":1541694321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718302594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":34,"alternative-id":["S0046817718302594"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.07.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}